Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoGen Inc (NASDAQ:IMGN)

6.06
Delayed Data
As of Jun 23
 +0.24 / +4.12%
Today’s Change
1.51
Today|||52-Week Range
6.39
+197.06%
Year-to-Date
ImmunoGen (IMGN) Jumps: Stock Rises 10.4%
Jun 21 / Zacks.com - Paid Partner Content
Why Is ImmunoGen (IMGN) Stock Up 131% This Year?
Jun 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close5.82
Today’s open5.78
Day’s range5.67 - 6.09
Volume2,791,029
Average volume (3 months)2,414,289
Market cap$541.4M
Dividend yield--
Data as of 4:00pm ET, 06/23/2017

Growth & Valuation

Earnings growth (last year)-154.93%
Earnings growth (this year)+13.67%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)-49.72%
P/E ratioNM
Price/Sales4.13
Price/Book--

Competitors

 Today’s
change
Today’s
% change
NTLAIntellia Therapeutic...-0.20-1.31%
AUPHAurinia Pharmaceutic...+0.24+3.76%
ANIPANI Pharmaceuticals ...+0.48+1.02%
JNCEJounce Therapeutics ...+0.47+2.77%
Data as of 4:14pm ET, 06/23/2017

Financials

Next reporting dateJuly 28, 2017
EPS forecast (this quarter)-$0.40
Annual revenue (last year)$43.0M
Annual profit (last year)-$157.8M
Net profit margin-366.80%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark J. Enyedy
Chief Financial Officer &
Executive Vice President
David B. Johnston
Corporate headquarters
Waltham, Massachusetts

Forecasts